Core Viewpoint - Ademi LLP is investigating Equitable Holdings Inc. for potential breaches of fiduciary duty and other legal violations related to its merger with Corebridge, raising concerns about whether shareholders are receiving a fair price [1][4]. Transaction Details - Equitable stockholders will receive 1.55516 shares of the new parent company in an all-stock merger valued at approximately $22 billion, based on closing stock prices as of March 25, 2026 [3]. - Post-transaction, Corebridge shareholders will own about 51% of the combined entity, while Equitable shareholders will hold approximately 49% [3]. Board Conduct and Limitations - The transaction agreement imposes significant penalties on Equitable for accepting competing bids, which may limit the board's ability to act in the best interest of all shareholders [4]. - The investigation focuses on whether the Equitable board is fulfilling its fiduciary duties to shareholders amidst these limitations [4].

Core Insights - Moore Law PLLC is investigating potential claims against the officers and directors of Terran Orbital Corporation related to the merger with Lockheed Martin Corporation on October 30, 2024 [1] - The investigation focuses on allegations that former CEO Marc Bell conspired with Lockheed Martin to merge at an unfair price of $0.25 per share, while he received a $6 million payment [1] - Reports indicate that Bell had previously claimed Terran Orbital shares were worth more than Lockheed's initial offer of $1.00 per share, suggesting a significant undervaluation for shareholders [1] Investigation Details - The law firm is reaching out to shareholders who owned Terran Orbital stock on the merger date and received $0.25 per share [1] - Shareholders may seek monetary damages, corporate governance reforms, and reimbursement at no cost, as representation is on a contingency fee basis [1]

Core Viewpoint - Ademi LLP is investigating Lisata Therapeutics Inc. for potential breaches of fiduciary duty and other legal violations related to its transaction with Kuva Labs Inc. [1] Group 1: Transaction Details - Lisata stockholders will receive $5.00 per share in cash plus one contingent value right per share, which could provide an additional $1.00 per share if a New Drug Application for certepetide is filed or accepted by the FDA within seven years of closing [1]. - The transaction agreement imposes significant penalties on Lisata for accepting competing bids, which raises concerns about the fairness of the deal for shareholders [1]. Group 2: Investigation Focus - The investigation is centered on the conduct of Lisata's board of directors and whether they are fulfilling their fiduciary duties to all shareholders [1]. - Ademi LLP specializes in shareholder litigation involving buyouts, mergers, and individual shareholder rights, indicating a focus on protecting shareholder interests [1].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of SelectQuote, Inc. in light of a federal securities lawsuit alleging misrepresentation and failure to disclose critical information regarding the company's practices related to Medicare beneficiaries [1][2]. Group 1: Allegations Against SelectQuote - The lawsuit claims that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of the quality of those plans [2]. - It is alleged that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans [2]. - The company is accused of receiving illegal kickbacks to steer beneficiaries towards certain insurers while limiting enrollment in competitors' plans [2]. - SelectQuote is said to have failed to comply with applicable laws and regulations, making it vulnerable to regulatory and legal sanctions, including potential violations of the False Claims Act [2]. - Positive statements made by SelectQuote regarding its business and operations are claimed to be materially misleading and lacking a reasonable basis due to the aforementioned issues [2]. Group 2: Shareholder Actions - Shareholders who purchased SLQT before September 9, 2020, are encouraged to contact Kuehn Law, which covers all case costs and does not charge its clients [3]. - The firm emphasizes the importance of shareholder participation in maintaining the integrity and fairness of financial markets [4].

Group 1 - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Unicycive Therapeutics, Inc. [1] - A federal securities lawsuit alleges that insiders at Unicycive Therapeutics misrepresented the company's ability to meet FDA manufacturing compliance requirements and overstated the regulatory prospects of the OLC NDA [2] - Public statements made by Unicycive Therapeutics were claimed to be materially false and misleading at all relevant times due to these misrepresentations [2] Group 2 - Shareholders who purchased UNCY shares prior to March 29, 2024, are encouraged to contact Kuehn Law for potential legal action, as there may be limited time to enforce their rights [3] - Kuehn Law covers all case costs and does not charge its investor clients, emphasizing the importance of shareholder participation in maintaining market integrity [4]

Group 1 - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Snap, Inc. [1] - A federal securities lawsuit alleges that insiders at Snap misrepresented or failed to disclose significant adverse facts regarding the company's advertising revenue growth rate, which dropped from 9% in the first quarter to only 1% in April due to execution failures [2] - Shareholders who purchased SNAP shares prior to April 29, 2025, are encouraged to contact Kuehn Law, as there may be limited time to enforce their rights [3] Group 2 - The involvement of shareholders is emphasized as crucial for maintaining the integrity and fairness of financial markets [4]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of PubMatic, Inc. related to misrepresentation of the company's business and operations [1]. Group 1: Allegations of Misrepresentation - A federal securities lawsuit claims that insiders at PubMatic misrepresented or failed to disclose material adverse facts about the company's business, operations, and prospects [2]. - Specific allegations include the failure to disclose that a major Demand-Side Platform (DSP) buyer was shifting clients to a new platform, leading to a reduction in ad spend and revenue for PubMatic [2]. - As a result of these undisclosed facts, positive statements made about the company's business and prospects were deemed materially misleading [2]. Group 2: Shareholder Actions - Shareholders who purchased PUBM shares prior to February 27, 2025, are encouraged to contact Kuehn Law for potential legal action, as there may be limited time to enforce their rights [3]. - Kuehn Law offers to cover all case costs and does not charge its investor clients, emphasizing the importance of shareholder involvement in maintaining market integrity [4].

Core Viewpoint - Ademi LLP is investigating KORE Group Holdings Inc. for potential breaches of fiduciary duty and other legal violations related to its acquisition by Searchlight Capital Partners and Abry Partners, focusing on whether shareholders are receiving a fair price [1] Group 1: Transaction Details - KORE stockholders are set to receive $9.25 per share in an all-cash acquisition valued at approximately $726 million [1] - The transaction agreement imposes significant penalties on KORE if it accepts competing bids, which may limit shareholder options [1] Group 2: Investigation Focus - The investigation centers on the conduct of KORE's board of directors and whether they are fulfilling their fiduciary duties to all shareholders [1] - Ademi LLP specializes in shareholder litigation involving buyouts, mergers, and individual shareholder rights [1]

Group 1 - Ademi LLP is investigating Arcellx Inc. for potential breaches of fiduciary duty and other legal violations related to its transaction with Leonard Green & Partners [1] - In the transaction, Arcellx shareholders will receive $115 per share in cash plus a contingent value right of $5 per share, leading to an implied equity value of $7.8 billion at closing [1] - The $5 contingent value right is contingent upon achieving cumulative global net sales of at least $6 billion from launch through year-end 2029 [1] Group 2 - The transaction agreement imposes significant penalties on Arcellx for accepting competing bids, which may limit the board's ability to act in the best interest of all shareholders [1] - The investigation focuses on whether the Arcellx board of directors is fulfilling its fiduciary duties to all shareholders amidst the change of control arrangements that benefit insiders [1]

Group 1 - Ademi LLP is investigating IHS Holding Limited for potential breaches of fiduciary duty and other legal violations related to its transaction with MTN Group Limited [1] - The transaction involves IHS Holding stockholders receiving $8.50 per share in an all-cash deal valued at approximately $6.2 billion in enterprise value [1] - The transaction agreement imposes significant penalties on IHS Holding for accepting competing bids, which raises concerns about the board's fiduciary duties to shareholders [1]